<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005790</url>
  </required_header>
  <id_info>
    <org_study_id>NU 95C1</org_study_id>
    <secondary_id>NU-95C1</secondary_id>
    <secondary_id>NCI-G00-1738</secondary_id>
    <nct_id>NCT00005790</nct_id>
  </id_info>
  <brief_title>Perfusion Magnetic Resonance Imaging in Measuring the Growth of Blood Vessels in Newly Diagnosed Brain Tumors</brief_title>
  <official_title>Perfusion Magnetic Resonance Imaging of Brain Tumors: Correlation With Indicators of Angiogenesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <brief_summary>
    <textblock>
      RATIONALE: Perfusion magnetic resonance imaging may be an effective method of measuring the
      growth of blood vessels in brain tumors. These measurements may help doctors better diagnose
      and treat brain tumors.

      PURPOSE: Pilot study to determine the effectiveness of perfusion magnetic resonance imaging
      in measuring the growth of blood vessels in newly diagnosed brain tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Correlate the findings of perfusion magnetic resonance imaging with known
      tissue and serum markers of angiogenesis in patients with newly diagnosed surgically
      resectable brain tumors.

      OUTLINE: Patients undergo perfusion magnetic resonance imaging (MRI) scanning with contrast
      in conjunction with preoperative conventional MRI scanning with contrast. Patients receive
      gadopentetate dimeglumine IV over 5 seconds prior to perfusion MRI. Gadopentetate dimeglumine
      is administered at a slower rate prior to conventional MRI. Patients undergo blood draw to
      determine urokinase type plasminogen activator levels. After completion of perfusion and
      conventional MRI scanning, brain tumor tissue samples are obtained during surgical resection
      to determine tumor grade and type and urokinase type plasminogen activator and basic
      fibroblast growth factor levels. If CSF removal is required during surgery, then CSF samples
      are collected to determine urokinase type plasminogen activator and basic fibroblast growth
      factor levels.

      PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Unable to accrue subjects.
  </why_stopped>
  <start_date>April 1996</start_date>
  <completion_date>May 1999</completion_date>
  <primary_completion_date>May 1999</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Diagnostic</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>magnetic resonance imaging</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>gadopentetate dimeglumine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Newly diagnosed surgically resectable brain tumor

        PATIENT CHARACTERISTICS: Age: Over 18 Performance status: Not specified Life expectancy:
        Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified
        Other: Able to tolerate gadopentetate dimeglumine contrast Medically stable

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
        chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy Surgery:
        See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hunt H. Batjer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Robert H. Lurie Cancer Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2000</study_first_submitted>
  <study_first_submitted_qc>June 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2004</study_first_posted>
  <last_update_submitted>June 8, 2012</last_update_submitted>
  <last_update_submitted_qc>June 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult brain stem glioma</keyword>
  <keyword>adult ependymoma</keyword>
  <keyword>adult craniopharyngioma</keyword>
  <keyword>adult medulloblastoma</keyword>
  <keyword>adult meningioma</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult oligodendroglioma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult myxopapillary ependymoma</keyword>
  <keyword>adult anaplastic ependymoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult mixed glioma</keyword>
  <keyword>adult pineal parenchymal tumor</keyword>
  <keyword>adult central nervous system germ cell tumor</keyword>
  <keyword>adult pilocytic astrocytoma</keyword>
  <keyword>adult subependymoma</keyword>
  <keyword>adult diffuse astrocytoma</keyword>
  <keyword>adult ependymoblastoma</keyword>
  <keyword>adult pineocytoma</keyword>
  <keyword>adult pineoblastoma</keyword>
  <keyword>adult meningeal hemangiopericytoma</keyword>
  <keyword>adult choroid plexus tumor</keyword>
  <keyword>adult grade III meningioma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

